Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety
of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase,
as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients
with a parallel non-randomized Control Arm for treatment with standard of care only.